Clascoterone for Hair Loss: Do the Phase 3 Results Live Up to the Hype?

Updated 25 September 2026: No new clascoterone Phase 3 clinical dataset has been released since this article was published. Expert commentary on the 12-month results has been positive, and an August 2026 peer-reviewed review highlighted the large gap between the 539% and 168% results reported across the two Phase 3 trials. Absolute hair-count data and the full peer-reviewed Phase 3 paper are still unavailable. Read the full update ↓

A patient sent me a screenshot of a news headline recently, with a single question written above it:

The headline was hard to ignore. A new topical treatment had reportedly produced a 539% improvement in hair count.

That number created a great deal of excitement around clascoterone, the medication being developed for male pattern hair loss under the name Breezula. Some people are already calling it a replacement for finasteride. Others describe it as the first real breakthrough in hair loss treatment for decades.

I think both reactions are premature.

Clascoterone is genuinely interesting. Its mechanism makes sense, the Phase 3 program was large, and the 12-month data deserve attention. But a large percentage in a press release does not necessarily mean a dramatic change when a patient looks in the mirror.

So let us look at what we actually know, what remains unpublished, and where clascoterone may realistically fit into the treatment of male pattern hair loss.

The six-month Phase 3 studies reported statistically significant improvements in target-area hair count, and Cosmo later reported continued gains among responders who stayed on treatment through 12 months. For now, three limits matter most:

• Clascoterone is not yet approved as a hair loss treatment anywhere.
• The complete Phase 3 dataset has not yet been published in a peer-reviewed medical journal.
• The widely reported 539% figure is a relative comparison against the vehicle solution, not a 539% increase in the patient's total hair density.

Clascoterone may eventually become useful for preserving hair and slowing androgen-driven miniaturization. The evidence available today does not justify calling it a miracle regrowth treatment or a proven replacement for finasteride.

What is clascoterone?

Clascoterone is a medication that blocks androgen receptors locally.

Androgenetic alopecia develops when genetically susceptible hair follicles respond to androgen signaling, particularly dihydrotestosterone, or DHT. Over time, affected follicles become smaller. The growing phase shortens, the hair shaft becomes finer, and visible scalp coverage gradually decreases.

Finasteride approaches this process by reducing the conversion of testosterone into DHT.

Clascoterone takes a different route. Instead of substantially lowering the production of DHT, it is designed to compete with DHT at the androgen receptor in the skin and hair follicle. In simple terms, it attempts to prevent DHT from delivering its message to the follicle.

That distinction matters:

• Finasteride reduces DHT production.
• Clascoterone attempts to block DHT signaling at the receptor.
• Minoxidil works through a different pathway again, supporting the hair-growth cycle rather than directly blocking androgen signaling.

Clascoterone is not an entirely new substance. A 1% cream formulation is already approved in the United States under the brand name Winlevi for acne, with an initial US approval dating to 2020. The hair loss product being studied is a different formulation: a 5% topical scalp solution developed specifically for androgenetic alopecia.

Why is clascoterone attracting so much attention?

The appeal is not difficult to understand.

Many men are concerned about the possible systemic effects of oral anti-androgen treatments. Some tolerate finasteride very well. Others prefer not to use it, or stop because of side effects, or because of anxiety about side effects.

A topical medication that acts primarily at the scalp androgen receptor could potentially offer another option. Clascoterone is also rapidly converted into less active metabolites after entering the body, so earlier studies have raised the possibility of reducing androgen activity in the scalp while limiting systemic exposure.

The mechanism is attractive on paper. What matters clinically is whether it preserves or improves enough hair to make a visible difference, while remaining safe and practical over years of use.

Hair loss is not treated for six weeks. Androgenetic alopecia is progressive, and treatment may need to continue for many years.

What were the SCALP 1 and SCALP 2 studies?

According to the sponsor, SCALP 1 and SCALP 2 were identically designed Phase 3 trials of clascoterone 5% solution.

Together, the studies enrolled 1,465 adult men with mild-to-moderate androgenetic alopecia across 51 centers in the United States and Europe.

During the first six months, participants were assigned to use either clascoterone 5% topical solution or a vehicle solution containing the formulation without the active medication. The solution was applied twice daily to the affected areas of the scalp. The studies measured changes in non-vellus target-area hair count and included patient-reported assessments of scalp coverage and treatment satisfaction.

A vehicle is not simply water. It contains the delivery ingredients used in the treatment but excludes the active drug. Comparing the medication with its vehicle helps researchers determine whether any benefit comes from clascoterone itself, rather than from the base formulation or from the simple act of regularly applying a product to the scalp.

What did the six-month Phase 3 results show?

In December 2025, Cosmo Pharmaceuticals announced topline results from both Phase 3 studies. According to the company:

• Both studies achieved statistically significant improvements in target-area hair count.
• One trial showed a 5.39-fold, or 539%, relative improvement versus vehicle.
• The other showed a 1.68-fold, or 168%, relative improvement versus vehicle.
• Treatment-emergent adverse events were reportedly similar between clascoterone and vehicle.
• The combined patient-reported outcome analysis was statistically significant.

Both independently conducted studies reached the objective hair-count endpoint, which is a useful signal. The harder question is what those relative figures mean in absolute and cosmetic terms.

Does 539% mean five times more hair?

No.

It does not mean that patients increased their total amount of hair by 539%. It does not mean that a visibly bald area became five times denser. It also does not mean the treatment was 539% as effective as finasteride or minoxidil.

The number describes a relative difference between clascoterone and the vehicle group. A relative percentage can look enormous when the change in the comparison group is small.

Imagine the vehicle group gained an average of one hair in a measured area while the treatment group gained around six. The treatment result could then be described as several hundred percent greater than vehicle, even though the absolute difference was only about five hairs.

Those numbers are only an illustration, not the actual Phase 3 results. The problem is that detailed absolute hair-count changes for each group have not yet been fully published in a peer-reviewed paper. Without those figures, it is difficult to judge how large the cosmetic improvement really was.

Statistical significance is not the same as visible significance

Hair-count studies need numerical endpoints. Researchers require an objective method of comparing one treatment with another, and a fixed target area measured under standardized conditions is the accepted way to do it.

Patients, however, do not examine their scalp through a small fixed target area. They look at:

• How much scalp is visible under normal lighting
• Whether the frontal area frames the face better
• Whether styling has become easier
• Whether the crown still appears open in photographs
• Whether the progression of hair loss has stopped

A treatment can produce a statistically significant improvement without creating a dramatic visual transformation. The opposite occasionally happens as well: a relatively modest numerical change may look better than expected if hairs become thicker, darker or easier to style.

This is why I prefer to evaluate hair loss treatments using several forms of evidence together: absolute change in hair count, change in hair shaft caliber, standardized clinical photography, patient-reported improvement, long-term preservation of existing hair, and safety and treatment adherence. A relative percentage on its own cannot cover all of that.

What did the new 12-month data show?

In April 2026, Cosmo announced the 12-month extension results from the Phase 3 program.

The extension included patients who had responded during the first six months. These participants were reassigned either to continue clascoterone or to switch from clascoterone to the vehicle solution.

Patients who remained on clascoterone for the full 12 months reportedly achieved a statistically significant 2.39-fold improvement in target-area hair count compared with patients who used clascoterone for six months and then switched to vehicle. The continuous-treatment group continued gaining hair between months 3 and 12. Patients who stopped active treatment after month 6 lost some of the hair-count benefit. Treatment satisfaction was also reported to be 24.5% better on a relative basis in the continuous-treatment group.

This is useful for two reasons.

First, it suggests that the effect may continue beyond six months. That matters, because hair treatments often require patience and six months may not reveal their complete benefit.

Second, the decline after treatment was stopped suggests that clascoterone will probably need to be used continuously. That would not make it unusual. The benefits of finasteride and minoxidil also depend on continued treatment. Genetic hair loss does not disappear because a medication worked for several months.

There is an important detail in the extension design, though: only patients classified as responders during the first part were eligible for this stage. The 12-month findings therefore tell us about the durability of treatment among selected responders. They do not mean that every person starting clascoterone will continue improving for a full year.

How safe does clascoterone appear?

The reported safety results are one of the most interesting parts of the program.

According to the company, the 12-month safety and tolerability profile was comparable with vehicle, and no significant systemic hormonal side effects were observed. The company also described systemic absorption as negligible based on earlier clinical work.

The company-reported safety profile is reassuring so far, but the complete Phase 3 adverse-event tables still matter. As of September 2026, they have not been published in a peer-reviewed medical journal. Cosmo has stated that it intends to submit the full dataset for publication.

We therefore still need to see:

• The exact frequency of local irritation
• Discontinuation rates
• Laboratory and hormonal findings
• Whether any adverse effects differed according to age or treatment duration
• How the 5% scalp solution compares with existing therapies in routine use

Clascoterone update (September 2026): more expert confidence, but still not the data we need

Clascoterone has stayed in the dermatology news since I first published this article on 5 August 2026, but no new Phase 3 dataset has been released.

In September 2026, Joshua Zeichner, MD, associate professor of dermatology at Mount Sinai Hospital in New York, discussed the 12-month findings in a Dermatology Times expert video. He described the continued improvement reported through 12 months and the tolerability profile, which was similar to vehicle, as encouraging. He also suggested that a topical androgen receptor blocker could eventually become a foundational treatment for male pattern hair loss.

I can see why he is optimistic. Blocking androgen signaling at the scalp, rather than lowering DHT throughout the body as oral finasteride does, is the main reason this drug interests me too. His comments, however, rest on the same sponsor-reported Phase 3 results discussed above. No new trial or dataset sits behind them.

Even specialist coverage can blur the 12-month figures. The same Dermatology Times report described the result as a 2.39% increase from baseline in target-area hair density, whereas Cosmo's April 2026 announcement reported a 2.39-fold relative improvement compared with responders who switched to vehicle after month 6. A percentage change from baseline and a fold difference versus another group answer different questions, so the distinction matters when the result is summarized.

Why do the two Phase 3 trials differ so much?

A peer-reviewed narrative review published in August 2026 focused mainly on clascoterone for acne but also examined the hair-loss program. The authors wrote that the gap between two trials the sponsor describes as identically designed requires "careful explanation": a 5.39-fold (539%) relative improvement versus vehicle in one trial and 1.68-fold (168%) in the other.

Some variability between hair-growth trials is expected. Baseline severity, patient populations, study sites and measurement variability can all contribute. These figures are also ratios against vehicle, which means a small change in the vehicle group can make the relative difference look much larger.

None of this invalidates either trial. It just makes me want the absolute numbers even more.

As of September 2026, we still do not have:

• The absolute change in target-area hair count in each treatment group
• The complete adverse-event tables
• Detailed standardized clinical photography
• The full peer-reviewed Phase 3 publication

So my view is much the same as it was in August. The mechanism still makes sense to me, and Cosmo's April 2026 results suggest that responders who stay on treatment keep or add to their hair-count gains. But the more attention a drug gets before its full data are out, the more careful we need to be with the word "breakthrough".

Is clascoterone better than finasteride?

We do not know.

The Phase 3 studies compared clascoterone with its vehicle, not with oral finasteride, topical finasteride, dutasteride or minoxidil.

It is therefore not scientifically accurate to say that clascoterone is more effective than finasteride, as effective as finasteride, safer than finasteride in every respect, or a direct replacement for finasteride.

Those questions require head-to-head clinical studies, or at minimum detailed comparative evidence using similar endpoints and treatment periods.

Clascoterone may eventually prove particularly valuable for men who do not want to use an oral anti-androgen. It may also have a future role in combination treatment. But these possibilities should not be presented as established facts before the evidence exists.

Could clascoterone be combined with minoxidil?

From a biological perspective, combining them may make sense. Clascoterone aims to reduce androgen signaling at the follicle. Minoxidil supports the growth cycle through a different mechanism. One treatment could potentially help protect the follicle from further androgen-driven miniaturization while the other supports growth.

We still need clinical evidence showing whether the combination works better than either treatment alone, whether applying both products increases irritation, what the best order and timing of application is, and whether long-term adherence is realistic with twice-daily treatment.

A treatment can work very well in a controlled clinical trial and still struggle in daily life if it is inconvenient, expensive, greasy or irritating.

Could women use clascoterone for hair loss?

The major Phase 3 SCALP trials were conducted in men. We cannot automatically apply the same efficacy and safety conclusions to female pattern hair loss.

Androgen signaling plays a clear role in male androgenetic alopecia. In women, the biology can be more complex, and diffuse thinning may also relate to iron deficiency, thyroid problems, hormonal changes, nutritional deficiencies, medication, chronic telogen effluvium or other medical conditions.

Topical anti-androgen treatments may eventually prove useful for selected female patients, but dedicated studies are needed before firm conclusions can be drawn. A 2025 clinical review similarly described topical anti-androgens as an emerging area rather than an established replacement for currently approved treatment.

Can clascoterone replace a hair transplant?

Not in areas where the follicles have already been permanently lost.

Medication and hair transplantation solve different parts of the problem.

Medical treatment is most useful for:

• Protecting existing hair
• Slowing further miniaturization
• Thickening follicles that are still alive but weakened
• Reducing future progression
• Supporting the long-term stability of a hair transplant result

Hair transplantation moves healthy follicular units from a suitable donor area to areas where natural coverage is no longer sufficient.

If an area has been bald for many years and viable follicles are no longer present, even a strong medical response is unlikely to recreate the density that can be achieved by transplanting appropriate grafts.

The best long-term plans often use both approaches intelligently. Surgery restores selected areas, while medical treatment protects as much of the patient's original hair as possible. A hair transplant does not stop the biological process of androgenetic alopecia.

Could clascoterone be useful after a hair transplant?

Potentially, yes.

One of the most important parts of hair transplant planning is not simply deciding how many grafts can be placed today. We also need to consider what the patient's untreated hair may look like five or ten years later.

A transplant can remain technically successful while the surrounding native hair continues to thin, which is why stabilizing progressive hair loss matters.

If clascoterone is eventually approved and proves effective in ordinary clinical use, it may become another option for preserving non-transplanted hair before or after surgery. At present, however, this remains a potential future use. Clascoterone 5% solution is still investigational for androgenetic alopecia.

When could Breezula become available?

Cosmo confirmed in July 2026 that the Phase 3 clinical program had been completed and that regulatory preparations were continuing.

The company currently expects to submit its US application in the first quarter of 2027 and its European application in the second quarter of 2027. Those are planned submission dates, not approval dates. Regulators must still review the full efficacy, safety, manufacturing and labeling data.

As of September 2026:

• Breezula is not approved for male pattern hair loss.
• There is no confirmed commercial launch date.
• The final price has not been announced.
• The complete Phase 3 paper has not yet been published.

What I still want to see

Clascoterone has enough positive evidence to deserve serious attention. The Phase 3 program included a large number of men, both pivotal trials reached their objective hair-count endpoints, and the 12-month extension suggests continued activity while treatment is maintained.

The 539% headline claims far more than the published detail can currently support. We have still not seen the absolute changes in hair count, full standardized photographs, detailed safety tables or an independent peer-reviewed analysis.

I also want to know how clascoterone performs beside treatments we already use. Head-to-head data with finasteride would be especially useful, as would combination data with minoxidil. Long-term adherence and price will matter too if the final product requires twice-daily use for years. Those practical questions will shape its real clinical value.

The point we often miss in hair loss treatment

Patients naturally focus on regrowth. They want to know how many new hairs a treatment can produce.

But in androgenetic alopecia, preservation is often just as important.

A treatment that helps a 25-year-old keep his existing hair for the next decade may have enormous value, even if his six-month before-and-after photograph does not look dramatic.

Once a follicle has miniaturized beyond recovery, medication becomes much less useful. Preventing that loss is usually easier than trying to reverse it later.

Clascoterone may ultimately prove more valuable as a long-term follicle-protection treatment than as a spectacular regrowth treatment. If that turns out to be its role, it would still be clinically useful.

Frequently Asked Questions

My final view

Clascoterone is one of the most credible emerging treatments for male androgenetic alopecia.

Its local androgen receptor-blocking mechanism is different from the way finasteride reduces DHT production, and the latest Phase 3 announcements suggest measurable hair-count improvement, continued benefit through 12 months and a safety profile similar to vehicle.

The evidence still needs to be read carefully. The widely quoted 539% figure is a relative improvement against vehicle, not a 539% increase in total hair density. The full Phase 3 results have not yet appeared in a peer-reviewed publication, and clascoterone has not been directly shown to outperform finasteride or minoxidil.

For now, Breezula looks scientifically credible and worth following closely, but the evidence does not yet support the revolutionary claims attached to some headlines.

So, to answer the patient who sent me that screenshot: no, I would not cancel a well-planned procedure to wait for a medication that is still at least a year away from a regulatory decision, and which was never designed to restore hair that has already been lost.

— Dr. Mesut Demir